UA111744C2 - ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk - Google Patents

ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk

Info

Publication number
UA111744C2
UA111744C2 UAA201315617A UAA201315617A UA111744C2 UA 111744 C2 UA111744 C2 UA 111744C2 UA A201315617 A UAA201315617 A UA A201315617A UA A201315617 A UAA201315617 A UA A201315617A UA 111744 C2 UA111744 C2 UA 111744C2
Authority
UA
Ukraine
Prior art keywords
pyridoporasins
replaced
syk inhibitors
syk
inhibitors
Prior art date
Application number
UAA201315617A
Other languages
English (en)
Inventor
Вей-Го Су
Вей Ден
Цзяньго Цзі
Original Assignee
Хатчісон Медіфарма Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47295336&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA111744(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Хатчісон Медіфарма Лімітед filed Critical Хатчісон Медіфарма Лімітед
Publication of UA111744C2 publication Critical patent/UA111744C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Представлені піридопіразинові сполуки формули (І), їх фармацевтичні композиції та способи їх застосування, де R, R, R, Rта m визначені в описі,I.
UAA201315617A 2011-06-08 2012-07-06 ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk UA111744C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2011/075431 WO2012167423A1 (en) 2011-06-08 2011-06-08 Substituted pyridopyrazines as novel syk inhibitors
PCT/CN2012/076576 WO2012167733A1 (en) 2011-06-08 2012-06-07 Substituted pyridopyrazines as novel syk inhibitors

Publications (1)

Publication Number Publication Date
UA111744C2 true UA111744C2 (uk) 2016-06-10

Family

ID=47295336

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201315617A UA111744C2 (uk) 2011-06-08 2012-07-06 ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk

Country Status (30)

Country Link
US (2) US9434726B2 (uk)
EP (1) EP2718293B1 (uk)
JP (2) JP5940148B2 (uk)
KR (1) KR101571720B1 (uk)
CN (1) CN103596952B (uk)
AU (1) AU2012266941B2 (uk)
CA (1) CA2836227C (uk)
CL (1) CL2013003512A1 (uk)
CY (1) CY1119953T1 (uk)
DK (1) DK2718293T3 (uk)
ES (1) ES2657549T3 (uk)
HK (1) HK1190143A1 (uk)
HR (1) HRP20180139T1 (uk)
HU (1) HUE037934T2 (uk)
IL (1) IL229410A (uk)
LT (1) LT2718293T (uk)
MX (1) MX355671B (uk)
MY (1) MY186599A (uk)
NO (1) NO2718293T3 (uk)
PE (1) PE20141167A1 (uk)
PL (1) PL2718293T3 (uk)
PT (1) PT2718293T (uk)
RS (1) RS56901B1 (uk)
RU (1) RU2569635C9 (uk)
SG (1) SG195035A1 (uk)
SI (1) SI2718293T1 (uk)
TW (1) TWI494311B (uk)
UA (1) UA111744C2 (uk)
WO (2) WO2012167423A1 (uk)
ZA (1) ZA201308947B (uk)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140005188A1 (en) * 2011-03-11 2014-01-02 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
WO2012167423A1 (en) * 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
EP2882722B1 (en) 2012-08-13 2016-07-27 Takeda Pharmaceutical Company Limited Quinoxaline derivatives as gpr6 modulators
WO2014086032A1 (en) * 2012-12-07 2014-06-12 Hutchison Medipharma Limited Substituted pyridopyrazines as syk inhibitors
JP6526034B2 (ja) 2014-02-14 2019-06-05 武田薬品工業株式会社 Ｇｐｒ６のピリドピラジンモジュレーター
LT3119772T (lt) 2014-03-19 2019-08-26 Boehringer Ingelheim International Gmbh Heteroarilo sik inhibitoriai
PE20180572A1 (es) * 2015-06-18 2018-04-04 Cephalon Inc Derivados de piperidina 1,4-sustituidos
ES2849951T3 (es) 2015-06-18 2021-08-24 89Bio Ltd Derivados de piperidina 4-bencil y 4-benzoil sustituidos
CN105153211B (zh) * 2015-09-22 2017-02-01 上海晋鲁医药科技有限公司 一种合成1‑(N‑Boc‑4‑哌啶)‑4‑吡唑硼酸频哪醇酯的方法
WO2018145525A1 (zh) 2017-02-08 2018-08-16 中国医药研究开发中心有限公司 吡咯并芳杂环类化合物及其制备方法和医药用途
EP4248968A3 (en) * 2017-07-18 2023-12-06 Merck Patent GmbH Tlr7/8 antagonists and uses thereof
CN109422741A (zh) * 2017-08-22 2019-03-05 和记黄埔医药（上海）有限公司 化合物的盐及其晶型
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN117425654A (zh) * 2021-06-04 2024-01-19 基因泰克公司 2,8-二氮杂螺[4.5]癸烷化合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022779A (en) * 1974-07-25 1977-05-10 E. R. Squibb & Sons, Inc. Amino derivatives of pyrido(3,4-b)pyrazine carboxylic acids and esters
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US20030158195A1 (en) * 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1538907A4 (en) * 2002-07-02 2008-12-24 Southern Res Inst FTSZ-HEMMER AND ITS USE
DE10323345A1 (de) * 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
RU2515944C9 (ru) * 2005-11-11 2014-07-20 Этерна Центарис ГмбХ ПРОИЗВОДНЫЕ ПИРИДОПИРАЗИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ФИЗИОЛОГИЧЕСКИХ И/ИЛИ ПАТОФИЗИОЛОГИЧЕСКИХ СОСТОЯНИЙ ПОСРЕДСТВОМ ИНГИБИРОВАНИЯ ФЕРМЕНТОВ ERK, ERK1, ERK2, PI3K, PI3Kальфа, PI3Kбета, PI3Kгамма, PI3Kдельта, PI3K-С2альфа, PI3K-С2бета, PI3K-Vps34р (ВАРИАНТЫ)
TW200942537A (en) 2008-02-01 2009-10-16 Irm Llc Compounds and compositions as kinase inhibitors
CA2732087A1 (en) 2008-08-05 2010-02-11 Boehringer Ingelheim International Gmbh Substituted naphthyridines and their use as medicaments
CN102574847A (zh) * 2009-07-30 2012-07-11 Irm责任有限公司 作为syk激酶抑制剂的化合物和组合物
ES2661850T3 (es) * 2009-09-14 2018-04-04 Gilead Sciences, Inc. Moduladores de receptores del tipo toll
EA201201052A1 (ru) 2010-01-29 2013-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные нафтиридины и их применение в качестве ингибиторов киназы syk
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
US20140005188A1 (en) * 2011-03-11 2014-01-02 Glaxo Group Limited Pyrido[3,4-b]pyrazine derivatives as syk inhibitors
WO2012167423A1 (en) * 2011-06-08 2012-12-13 Hutchison Medipharma Limited Substituted pyridopyrazines as novel syk inhibitors
BR112014001898A2 (pt) 2011-07-26 2017-02-21 Boehringer Ingelheim Int quinolinas substituídas e seu uso como medicamentos

Also Published As

Publication number Publication date
EP2718293A4 (en) 2014-12-03
HUE037934T2 (hu) 2018-09-28
KR20140025559A (ko) 2014-03-04
US20160324864A1 (en) 2016-11-10
HK1190143A1 (zh) 2014-06-27
JP6175484B2 (ja) 2017-08-02
CY1119953T1 (el) 2018-12-12
NO2718293T3 (uk) 2018-03-24
ES2657549T3 (es) 2018-03-05
IL229410A (en) 2017-08-31
NZ617765A (en) 2016-02-26
PE20141167A1 (es) 2014-09-03
RS56901B1 (sr) 2018-05-31
RU2569635C2 (ru) 2015-11-27
JP2016106100A (ja) 2016-06-16
SG195035A1 (en) 2013-12-30
RU2569635C9 (ru) 2016-10-20
JP5940148B2 (ja) 2016-06-29
ZA201308947B (en) 2020-02-26
WO2012167423A1 (en) 2012-12-13
PL2718293T3 (pl) 2018-05-30
CN103596952A (zh) 2014-02-19
CN103596952B (zh) 2016-05-04
WO2012167733A1 (en) 2012-12-13
TWI494311B (zh) 2015-08-01
DK2718293T3 (da) 2018-01-29
TW201305160A (zh) 2013-02-01
MY186599A (en) 2021-07-29
CA2836227C (en) 2016-08-16
LT2718293T (lt) 2018-02-12
SI2718293T1 (en) 2018-04-30
IL229410A0 (en) 2014-01-30
EP2718293B1 (en) 2017-10-25
KR101571720B1 (ko) 2015-11-25
EP2718293A1 (en) 2014-04-16
PT2718293T (pt) 2018-01-30
US20140121200A1 (en) 2014-05-01
CL2013003512A1 (es) 2014-07-18
CA2836227A1 (en) 2012-12-13
JP2014516059A (ja) 2014-07-07
HRP20180139T1 (hr) 2018-05-18
AU2012266941A1 (en) 2013-11-28
US10052330B2 (en) 2018-08-21
MX355671B (es) 2018-04-26
BR112013031405A2 (pt) 2016-12-06
RU2013158996A (ru) 2015-07-20
MX2013014242A (es) 2014-04-14
US9434726B2 (en) 2016-09-06
AU2012266941B2 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
UA111744C2 (uk) ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk
PH12017502141A1 (en) Compounds and their methods of use
EA201590534A1 (ru) Новые бициклические производные
UA114087C2 (xx) Похідні піридину
EA201400833A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
UY34414A (es) Composiciones hemostáticas
MX336381B (es) Boronatos como inhibidores de arginasa.
IN2014MN02598A (uk)
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
CR20130539A (es) Triazolopiridinas
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
UY33930A (es) Inhibidores novedosos de quinasas
UY34654A (es) Inhibidores de la beta-secretasa
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
EA201490846A1 (ru) Новые производные арилхинолина
EA201600124A1 (ru) Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их
UY34415A (es) Composiciones hemostáticas
EA201590552A1 (ru) Аминохинолины в качестве ингибиторов киназы
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
EA201591498A1 (ru) Азетидинилоксифенилпирролидиновые соединения